Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia.
The number of allogeneic transplants from unrelated donors has grown in the past decade in part because of the expansion of the donor registry size. Patient survival has improved due to the selection of more closely matched donors and the development of effective infection prophylaxis. Relapse-free survival remains limited in patients with a large tumor burden at the time of transplantation. A higher marrow cell dose is the major factor to minimize transplant-related death. Future studies of peripheral blood stem cell transplants should be considered for patients with acute leukemia with the goal of enhancing the stem cell dose and improving survival.
Anasetti
C
C
Fred Hutchinson Cancer Research Center and the University of Washington, Seattle 98109, USA.
D000208:Acute Disease; D000328:Adult; D016026:Bone Marrow Transplantation / Q000401:mortality; D002173:Cancer Care Facilities / Q000706:statistics & numerical data; D002452:Cell Count; D002648:Child; D018572:Disease-Free Survival; D005312:Fetal Blood / Q000166:cytology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007951:Leukemia, Myeloid / Q000401:mortality / Q000628:therapy*; D008212:Lymphocyte Depletion; D011446:Prospective Studies; D012074:Remission Induction; D016019:Survival Analysis; D013601:T-Lymphocytes; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014861:Washington